Ebewe Pharma

Activities: Manufacturing Hi Tech Manufacturing

Ebewe specialize in technologies and applications in the fields of specialty pharmaceuticals(immunology and oncology) and contract manufacturing.

Trending Articles

  1. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  4. Pharmaceutics International bolsters its prefilled syringe production capabilities The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
  5. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Pharmaceutical

Brussels approves acquisition of Ebewe by Novartis

<p>The European Commission has granted competition approval to the takeover of Austria's generic pharmaceuticals company Ebewe SP by Swiss drugmaker Novartis, enabling the Euro 1.3bn deal to go ahead. Although Novartis makes generic medicines through its Sandoz division, the EC concluded that the deal &quot;would not significantly impede effective competition&quot; in Europe. </p>
Media

Novartis to add EBEWE Pharma generic injectables business to Sandoz division

<p>Novartis is to acquire the generic injectables business of Austrian company EBEWE Pharma for Euro 925m (US$1.2bn), providing its Sandoz generic pharmaceuticals division with an opportunity to grow while improving access to many generic oncology medicines.</p>
Subscribe now